{"id":469,"date":"2025-08-23T16:58:02","date_gmt":"2025-08-23T11:28:02","guid":{"rendered":"https:\/\/www.najao.com\/learn\/?p=469"},"modified":"2026-04-06T17:20:00","modified_gmt":"2026-04-06T11:50:00","slug":"biomarkers","status":"publish","type":"post","link":"https:\/\/www.najao.com\/learn\/biomarkers\/","title":{"rendered":"Biomarkers: Vital Tools Transforming Medicine and Research"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Biomarkers are defined as measurable indicators of biological states, processes, or responses that broadly inform health, disease progression, and treatment outcomes<strong><sup>1<\/sup><\/strong>. The ability to detect, quantify, and analyze biomarkers is revolutionizing medicine and biological research as it facilitates earlier diagnosis, supports personalized therapies, and makes the process of drug development more efficient. By leveraging a wide range of data, including specific molecules, physiology, imaging, and digital data, biomarkers provide multidimensional insights that are critical to effective disease management and scientific discovery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Key characteristics of effective biomarkers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Effective biomarkers require high sensitivity to correctly identify individuals with disease, which helps to minimize false negatives that delay care<strong><sup>2<\/sup><\/strong>. Specificity, on the other hand, ensures that healthy individuals are not misclassified, thereby preventing unnecessary interventions<strong><sup>3<\/sup><\/strong>. Furthermore, biomarkers must ensure reproducibility across populations, laboratories, and time points, which is crucial as it guarantees confidence in measurements for clinical application<strong><sup>4<\/sup><\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These core qualities make biomarkers the most reliable diagnostic, prognostic, predictive, pharmacodynamic, safety, and susceptibility indicators that can optimize patient care and research outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Types of biomarkers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biomarkers vary markedly based on biological origin and clinical utility, which is reflective of the complexity of living systems and diverse healthcare needs.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Biological basis classifications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Molecular biomarkers range across genetic variants (mutations, single nucleotide polymorphisms), protein markers (antibodies, enzymes), metabolites (glucose, lipids), and epigenetic modifications (DNA methylation, histone changes)<strong><sup>5-12<\/sup><\/strong>. For instance, BRCA1\/2 mutations signal hereditary breast and ovarian cancer risk; PSA protein aids prostate cancer detection; glucose levels assess diabetes management<strong><sup>13, 14<\/sup><\/strong>.<\/li>\n\n\n\n<li>Physiological biomarkers indicate organ system performance such as blood pressure, heart rhythm patterns (eg, via ECG), respiratory function, and neurophysiological signals<strong><sup>15-18<\/sup><\/strong>.<\/li>\n\n\n\n<li>Histologic biomarkers based on tissue morphology and immunohistochemical staining enable cancer diagnosis, staging, and assessment of fibrosis or inflammation<strong><sup>19<\/sup><\/strong>.<\/li>\n\n\n\n<li>Radiographic biomarkers emerge from imaging like MRI, CT, PET, and are useful for conveying anatomical and functional disease data<strong><sup>20<\/sup><\/strong>.<\/li>\n\n\n\n<li>Digital biomarkers arise from wearables and smartphone apps that track activity, heart rate variability, sleep cycles, and mental status remotely and continuously<strong><sup>21<\/sup><\/strong>.<\/li>\n\n\n\n<li>Microbial biomarkers measure pathogen load or microbial community shifts across diverse environments like the <a href=\"https:\/\/www.najao.com\/learn\/gut-microbiome\/\" target=\"_blank\" rel=\"noreferrer noopener\">gut microbiome<\/a>, and this way the diagnosis of infectious diseases is improved while microbiome research is significantly advanced<strong><sup>22<\/sup><\/strong>.<\/li>\n\n\n\n<li>Immunological biomarkers incorporate autoantibody profiles, cytokine signaling patterns, and immune cell phenotypes relevant in immunodeficiency, autoimmunity, and cancer<strong><sup>23<\/sup><\/strong>.<\/li>\n\n\n\n<li>Environmental biomarkers detect exposure to heavy metals, pesticides, pollutants, and allergens, which are vital for epidemiological surveillance and public health interventions<strong><sup>24<\/sup><\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Clinical application categories<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Diagnostic biomarkers are useful for identifying disease presence. Examples include troponin in myocardial infarction or PCR for infectious pathogens, which enables timely intervention<strong><sup>25, 26<\/sup><\/strong>.<\/li>\n\n\n\n<li>Prognostic biomarkers are used to forecast disease progression or outcomes to aid long-term treatment planning, such as cancer staging systems or cardiovascular risk scores<strong><sup>27, 28<\/sup><\/strong>.<\/li>\n\n\n\n<li>Predictive biomarkers help to assess likely treatment responses, guiding personalized medicine. HER2 testing for trastuzumab suitability exemplifies this principle<strong><sup>29<\/sup><\/strong>.<\/li>\n\n\n\n<li>Pharmacodynamic biomarkers are used to evaluate biological responses to treatments to adjust dosing and enhance safety and efficiency, e.g., HbA1c in diabetes care<strong><sup>30<\/sup><\/strong>.<\/li>\n\n\n\n<li>Safety biomarkers are useful for signaling potential adverse effects or toxicity, which is crucial in monitoring drug therapies (eg, liver enzymes in hepatotoxicity)<strong><sup>31<\/sup><\/strong>.<\/li>\n\n\n\n<li>Susceptibility or risk biomarkers helps to identify individuals at heightened disease risk<strong><sup>32<\/sup><\/strong>. This enables preventative strategies through genetic, metabolic, or environmental profiling.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Notable examples and disease-specific applications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biomarkers vary widely based on the disease they diagnose, track, or predict. Here are notable examples across several critical health areas:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Cardiovascular disease<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">These biomarkers are vital for assessing heart function, inflammation, and risk of arterial disease.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Troponin:<\/strong> Used for the rapid diagnosis of heart attack<strong><sup>25<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Brain natriuretic peptide (BNP):<\/strong> A key indicator for assessing the severity and progression of heart failure<strong><sup>33<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>C-reactive protein (CRP):<\/strong> An inflammatory marker strongly linked to overall cardiovascular risk<strong><sup>34<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>LDL cholesterol:<\/strong> A primary marker used to assess risk and progression of plaque buildup in arteries<strong><sup>35<\/sup><\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Cancer<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">These examples illustrate biomarkers used for screening, progression monitoring, and guiding targeted treatments.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prostate-specific antigen (PSA)<\/strong>: Used primarily for prostate cancer screening and recurrence monitoring<strong><sup>14<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>CA-125<\/strong>: Used mainly for monitoring the progression and recurrence of ovarian cancer<strong><sup>36<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>HER2 expression<\/strong>: Essential for guiding targeted therapy (like Trastuzumab) in certain types of breast cancer<strong><sup>37<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Carcinoembryonic antigen (CEA):<\/strong> Used primarily for post-treatment surveillance in colorectal cancer<strong><sup>38<\/sup><\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Diabetes<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">These markers are used for diagnosis, management, and assessing endogenous insulin function.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Glycated hemoglobin (HbA1c)<\/strong>: Provides a measure of long-term glucose management, like the average glucose over 2-3 months<strong><sup>39<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Fasting plasma glucose<\/strong>: Used as a primary marker for diagnosis of diabetes<strong><sup>39<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>C-peptide<\/strong>: Indicates the level of endogenous insulin production by the pancreas<strong><sup>40<\/sup><\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Neurodegenerative diseases<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">These biomarkers help in the diagnosis and monitoring of complex <a href=\"https:\/\/www.najao.com\/learn\/neurodegeneration\/\" target=\"_blank\" rel=\"noreferrer noopener\">neurodegenerative<\/a> disorders.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Amyloid-beta and tau proteins<\/strong>: Core markers analyzed in cerebrospinal fluid or brain imaging for <a href=\"https:\/\/www.najao.com\/learn\/alzheimers-disease\/\" target=\"_blank\" rel=\"noreferrer noopener\">Alzheimer\u2019s<\/a> disease, and this way the presence of <strong><a href=\"https:\/\/www.najao.com\/learn\/protein-misfolding\/\" target=\"_blank\" rel=\"noreferrer noopener\">misfolded<\/a><\/strong> protein aggregates is confirmed<strong><sup>41<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Neurofilament light chain (NfL)<\/strong>: A signal of general neuronal injury often elevated in conditions like Parkinson\u2019s disease and Multiple Sclerosis<strong><sup>42, 43<\/sup><\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Infectious diseases<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">These markers confirm the presence of pathogens and determine the body&#8217;s response.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Viral load quantification<\/strong>: Measures the amount of virus (eg, HIV RNA) in the blood to monitor treatment efficacy<strong><sup>44<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>PCR-based pathogen detection<\/strong>: Used for rapid and precise identification of the pathogen&#8217;s genetic material (eg, COVID-19 testing)<strong><sup>45<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Antibody testing<\/strong>: Determines an individual&#8217;s infection or immunity status to a specific pathogen<strong><sup>46<\/sup><\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Applications across healthcare and research domains<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early disease detection<\/strong>: Biomarkers facilitate identification of pathological changes before clinical symptoms arise. This capability improves prognosis and can dramatically reduce healthcare costs by preventing advanced disease complications. For instance, the detection of elevated PSA levels or amyloid-beta accumulation helps to initiate earlier interventions in prostate cancer and Alzheimer\u2019s disease<strong><sup>14, 41<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Personalized medicine<\/strong>: Biomarkers allow <a href=\"https:\/\/www.najao.com\/learn\/precision-medicine\/\" target=\"_blank\" rel=\"noreferrer noopener\">tailoring therapies<\/a> based on individual molecular and phenotypic profiles, which can potentially enhance efficacy and minimize adverse effects. Examples include KRAS mutation status guiding colorectal cancer treatment choice and pharmacogenomic biomarkers predicting drug metabolism variants to avoid toxicity<strong><sup>47<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Clinical trials<\/strong>: Biomarkers help to expedite drug development by enabling precise patient selection, stratification, and response monitoring. This targeted approach increases success rates of trial and decreases costs<strong><sup>48<\/sup><\/strong>. Companion diagnostics paired with targeted therapies exemplify this synergy.<\/li>\n\n\n\n<li><strong>Public health<\/strong>: Biomarker surveillance is useful to monitor population exposure to environmental toxins, detect an <a href=\"http:\/\/www.najao.com\/learn\/antimicrobial-resistance\/\" target=\"_blank\" rel=\"noreferrer noopener\">AMR<\/a>-driven outbreak, or evaluate intervention efficacy. For example, blood lead levels track exposure in at-risk communities, and hence it is useful to guide public health policy<strong><sup>49<\/sup><\/strong>.<\/li>\n\n\n\n<li><strong>Agriculture and veterinary medicine<\/strong>: Biomarkers inform disease surveillance, breeding for resistance, and health monitoring<strong><sup>50-52<\/sup><\/strong>. Such applications contribute to food security and animal welfare by early disease detection and intervention.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Challenges and limitations in biomarker research<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Validation and standardization<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A major hurdle is demonstrating consistent, reproducible performance across diverse patient cohorts and laboratory platforms. Regulatory bodies like the FDA have established <a href=\"https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/about-biomarkers-and-qualification\">qualification programs<\/a> to standardize biomarker development and approval, but this process remains rigorous.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Contextual complexity<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Interpreting biomarker expression is complicated by influences from genetic background, epigenetics, environment, and lifestyle. This necessitates highly context-aware analysis to distinguish meaningful disease signals from confounding factors<strong><sup>53<\/sup><\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Biological system complexity<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Biomarkers often interact with multiple biological pathways. This inherent complexity presents significant challenges in accurately distinguishing a disease-specific signal from the noise generated by other biological processes<strong><sup>54<\/sup><\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Ethical and legal concerns<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For advanced markers (especially digital and genetic biomarkers), careful attention must be paid to data protection, informed consent, ownership, and algorithmic biases<strong><sup>55<\/sup><\/strong>. Furthermore, ensuring equitable access to biomarker technology is essential to mitigate widening health disparities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Future perspectives and innovations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The integration of <a href=\"http:\/\/www.najao.com\/learn\/multi-omics\/\" type=\"link\" id=\"www.najao.com\/learn\/multi-omics\/\" target=\"_blank\" rel=\"noreferrer noopener\">multi-omics<\/a> (genomics, transcriptomics, proteomics, metabolomics) enriches biomarker discovery and mechanistic insights, offering a systems biology view for better disease characterization<strong><sup>56<\/sup><\/strong>.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.najao.com\/learn\/liquid-biopsies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Liquid biopsies<\/a> revolutionize diagnosis and monitoring and thereby provide non-invasive access to circulating tumor DNA and cells<strong><sup>57<\/sup><\/strong>. This has potential applications expanding beyond oncology to cardiovascular and infectious diseases.<\/li>\n\n\n\n<li>Artificial intelligence and machine learning accelerate biomarker discovery by screening large, complex datasets<strong><sup>58<\/sup><\/strong>. This helps to unveil novel biomarker patterns, and improve predictive accuracy.<\/li>\n\n\n\n<li>The expansion of digital health technologies, including wearables and mobile apps, broadens digital biomarker repertoires<strong><sup>59<\/sup><\/strong>. This is useful to offer personalized, continuous health monitoring.<\/li>\n\n\n\n<li>Recent advances in computational biology, <a href=\"https:\/\/www.najao.com\/learn\/network-pharmacology\/\" target=\"_blank\" rel=\"noreferrer noopener\">network pharmacology<\/a>, and data integration are facilitating the development of personalized healthcare strategies. This includes biomarker-based early detection, individualized treatment plans, and enhanced patient monitoring<strong><sup>21, 60-61<\/sup><\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biomarkers are proving to be indispensable components of modern healthcare and biological research, finding usage across diagnosis, prognosis, treatment selection, safety monitoring, and epidemiology. Their expanding diversity, fueled by technological breakthroughs and analytical sophistication, has the potential to transform patient care through precision medicine. However, biomarker science can only realize its full potential in improving health outcomes and fostering innovation through continued interdisciplinary collaboration, rigorous validation, and ethical governance.<\/p>\n\n\n\n<!--nextpage-->\n\n\n\n<h2 class=\"wp-block-heading\">FAQs<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">1. What is the typical process for a novel biomarker to move from discovery to clinical use?<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The typical process involves three stages. It begins with discovery, which identifies potential biological candidates. This is followed by validation to test sensitivity in large cohorts, and consequently, the marker&#8217;s accuracy is confirmed. Ultimately, the process reaches qualification, thereby establishing clinical utility through the necessary regulatory approvals.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">2. Are all biomarkers physical substances, or can clinical observations qualify?<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">No. A biomarker is any measurable indicator. While often molecular, it can also be a physiological or digital measurement. Examples include gait speed tracked by a sensor or a specific pattern of tissue change observed in imaging.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">3. What does it mean for a biomarker to be &#8220;surrogate&#8221;?<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">A surrogate biomarker is an indicator used as a substitute for a definitive clinical endpoint, such as survival or irreversible progression. It is measured because it is easier, faster, or cheaper to assess in clinical trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Reference<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">1. Strimbu, K., &amp; Tavel, J. A. (2010). What are biomarkers?.&nbsp;<em>Current Opinion in HIV and AIDS<\/em>,&nbsp;<em>5<\/em>(6), 463-466.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">2. Mayeux, R. (2004). Biomarkers: potential uses and limitations.&nbsp;<em>NeuroRx<\/em>,&nbsp;<em>1<\/em>(2), 182-188.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">3. Pepe, M. S., Feng, Z., Janes, H., <em>et al<\/em>. (2008). Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.&nbsp;<em>Journal of the National Cancer Institute<\/em>,&nbsp;<em>100<\/em>(20), 1432-1438.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">4. Mattsson-Carlgren, N., Palmqvist, S., Blennow, K., <em>et al<\/em>. (2020). Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.&nbsp;<em>Nature communications<\/em>,&nbsp;<em>11<\/em>(1), 6252.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">5. Wang, Q., Chaerkady, R., Wu, J., <em>et al<\/em>. (2011). Mutant proteins as cancer-specific biomarkers.&nbsp;<em>Proceedings of the National Academy of Sciences<\/em>,&nbsp;<em>108<\/em>(6), 2444-2449.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">6. Sitinjak, B. D. P., Murdaya, N., Rachman, T. A., <em>et al<\/em>. (2023). The potential of single nucleotide polymorphisms (SNPs) as biomarkers and their association with the increased risk of coronary heart disease: a systematic review.&nbsp;<em>Vascular health and risk management<\/em>, 289-301.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">7. Monroy-Iglesias, M. J., Crescioli, S., Beckmann, K., <em>et al<\/em>. (2022). Antibodies as biomarkers for cancer risk: a systematic review.&nbsp;<em>Clinical and Experimental Immunology<\/em>,&nbsp;<em>209<\/em>(1), 46.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">8. Yang, H. Y., &amp; Lee, T. H. (2015). Antioxidant enzymes as redox-based biomarkers: a brief review.&nbsp;<em>BMB reports<\/em>,&nbsp;<em>48<\/em>(4), 200.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">9. Gounden, V., Devaraj, S., &amp; Jialal, I. (2024). The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes.&nbsp;<em>Lipids in Health and Disease<\/em>,&nbsp;<em>23<\/em>(1), 416.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">10. Zhou, X., Mao, J., Ai, J., <em>et al<\/em>. (2012). Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.&nbsp;<em>PloS one<\/em>,&nbsp;<em>7<\/em>(11), e48889.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">11. Levenson, V. V. (2010). DNA methylation as a universal biomarker.&nbsp;<em>Expert review of molecular diagnostics<\/em>,&nbsp;<em>10<\/em>(4), 481-488.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">12. Isharwal, S., Miller, M. C., Marlow, C., <em>et al<\/em>. (2008). p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.&nbsp;<em>The Prostate<\/em>,&nbsp;<em>68<\/em>(10), 1097-1104.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">13. Petrucelli, N., Daly, M. B., &amp; Pal, T. (2023). BRCA1-and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In&nbsp;<em>GeneReviews\u00ae[Internet]<\/em>. University of Washington, Seattle.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">14. Duffy, M. J. (2020). Biomarkers for prostate cancer: prostate-specific antigen and beyond.&nbsp;<em>Clinical Chemistry and Laboratory Medicine (CCLM)<\/em>,&nbsp;<em>58<\/em>(3), 326-339.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">15. Desai, M., Stockbridge, N., &amp; Temple, R. (2006). Blood pressure as an example of a biomarker that functions as a surrogate.&nbsp;<em>The AAPS journal<\/em>,&nbsp;<em>8<\/em>(1), 17.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">16. Ladejobi, A. O., Medina-Inojosa, J. R., Shelly Cohen, M., <em>et al<\/em>. (2021). The 12-lead electrocardiogram as a biomarker of biological age.&nbsp;<em>European Heart Journal-Digital Health<\/em>,&nbsp;<em>2<\/em>(3), 379-389.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">17. Ahookhosh, K., Gsell, W., Tielemans, B., <em>et al<\/em>. (2025). Respiratory rate as a X-ray-based biomarker for the longitudinal assessment of lung function and pathology.&nbsp;<em>Frontiers in Medicine<\/em>,&nbsp;<em>12<\/em>, 1621104.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">18. Javitt, D. C., Spencer, K. M., Thaker, G. K., <em>et al<\/em>. (2008). Neurophysiological biomarkers for drug development in schizophrenia.&nbsp;<em>Nature Reviews Drug Discovery<\/em>,&nbsp;<em>7<\/em>(1), 68-83.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">19. Cardiff, R. D., Gregg, J. P., Miller, J. W., <em>et al<\/em>. (2006). Histopathology as a predictive biomarker: strengths and limitations.&nbsp;<em>The Journal of nutrition<\/em>,&nbsp;<em>136<\/em>(10), 2673S-2675S.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">20. Bonmat\u00ed, L. M., Alberich-Bayarri, A., Garc\u00eda-Mart\u00ed, G., <em>et al<\/em>. (2012). Imaging biomarkers, quantitative imaging, and bioengineering.&nbsp;<em>Radiolog\u00eda (English Edition)<\/em>,&nbsp;<em>54<\/em>(3), 269-278.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">21. Coravos, A., Khozin, S., &amp; Mandl, K. D. (2019). Developing and adopting safe and effective digital biomarkers to improve patient outcomes.&nbsp;<em>NPJ digital medicine<\/em>,&nbsp;<em>2<\/em>(1), 14.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">22. Lun, H., Yang, W., Zhao, S., <em>et al<\/em>. (2019). Altered gut microbiota and microbial biomarkers associated with chronic kidney disease.&nbsp;<em>Microbiologyopen<\/em>,&nbsp;<em>8<\/em>(4), e00678.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">23. Disis, M. L. (2011). Immunologic biomarkers as correlates of clinical response to cancer immunotherapy.&nbsp;<em>Cancer immunology, immunotherapy<\/em>,&nbsp;<em>60<\/em>(3), 433-442.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">24. Kaviraj, A., Unlu, E., Gupta, A., <em>et al<\/em>. (2014). Biomarkers of environmental pollutants.&nbsp;<em>BioMed Research International<\/em>,&nbsp;<em>2014<\/em>, 806598.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">25. Aydin, S., Ugur, K., Aydin, S., <em>et al<\/em>. (2019). Biomarkers in acute myocardial infarction: current perspectives.&nbsp;<em>Vascular health and risk management<\/em>, 1-10.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">26. Li, H., Bai, R., Zhao, Z., <em>et al<\/em>. (2018). Application of droplet digital PCR to detect the pathogens of infectious diseases.&nbsp;<em>Bioscience Reports<\/em>,&nbsp;<em>38<\/em>(6), BSR20181170.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">27. Ankeny, J. S., Court, C. M., Hou, S., <em>et al<\/em>. (2016). Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.&nbsp;<em>British journal of cancer<\/em>,&nbsp;<em>114<\/em>(12), 1367-1375.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">28. Wang, J., Tan, G. J., Han, L. N., <em>et al<\/em>. (2017). Novel biomarkers for cardiovascular risk prediction.&nbsp;<em>Journal of geriatric cardiology: JGC<\/em>,&nbsp;<em>14<\/em>(2), 135.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">29. Barron, J. J., Cziraky, M. J., Weisman, T., <em>et al<\/em>. (2009). HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.&nbsp;<em>The oncologist<\/em>,&nbsp;<em>14<\/em>(8), 760-768.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">30. Lyons, T. J., &amp; Basu, A. (2012). Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers.&nbsp;<em>Translational Research<\/em>,&nbsp;<em>159<\/em>(4), 303-312.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">31. Gao, Y., Cao, Z., Yang, X., <em>et al<\/em>. (2017). Proteomic analysis of acetaminophen\u2010induced hepatotoxicity and identification of heme oxygenase 1 as a potential plasma biomarker of liver injury.&nbsp;<em>PROTEOMICS\u2013Clinical Applications<\/em>,&nbsp;<em>11<\/em>(1-2), 1600123.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">32. Ryan, P. B., Burke, T. A., Cohen Hubal, E. A., <em>et al<\/em>. (2007). Using biomarkers to inform cumulative risk assessment.&nbsp;<em>Environmental Health Perspectives<\/em>,&nbsp;<em>115<\/em>(5), 833-840.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">33. Kr\u00fcger, S., Graf, J. \u00dc., Kunz, D., <em>et al<\/em>. (2002). Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure.&nbsp;<em>Journal of the American College of Cardiology<\/em>,&nbsp;<em>40<\/em>(4), 718-722.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">34. Dhingra, R., Gona, P., Nam, B. H., <em>et al<\/em>. (2007). C-reactive protein, inflammatory conditions, and cardiovascular disease risk.&nbsp;<em>The American journal of medicine<\/em>,&nbsp;<em>120<\/em>(12), 1054-1062.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">35. Koenig, W., &amp; Khuseyinova, N. (2007). Biomarkers of atherosclerotic plaque instability and rupture.&nbsp;<em>Arteriosclerosis, thrombosis, and vascular biology<\/em>,&nbsp;<em>27<\/em>(1), 15-26.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">36. Esselen, K. M., Cronin, A. M., Bixel, K., <em>et al<\/em>. (2016). Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer.&nbsp;<em>JAMA oncology<\/em>,&nbsp;<em>2<\/em>(11), 1427-1433.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">37. Perrier, A., Gligorov, J., Lefevre, G., <em>et al<\/em>. (2018). The extracellular domain of Her2 in serum as a biomarker of breast cancer.&nbsp;<em>Laboratory Investigation<\/em>,&nbsp;<em>98<\/em>(6), 696-707.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">38. Wang, R., Wang, Q., &amp; Li, P. (2023). Significance of carcinoembryonic antigen detection in the early diagnosis of colorectal cancer: A systematic review and meta-analysis.&nbsp;<em>World Journal of Gastrointestinal Surgery<\/em>,&nbsp;<em>15<\/em>(12), 2907.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">39. Chung, J. K. O., Xue, H., Pang, E. W. H., <em>et al<\/em>. (2017). Accuracy of fasting plasma glucose and hemoglobin A1c testing for the early detection of diabetes: A pilot study.&nbsp;<em>Frontiers in Laboratory Medicine<\/em>,&nbsp;<em>1<\/em>(2), 76-81.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">40. Maddaloni, E., Bolli, G. B., Frier, B. M., <em>et al<\/em>. (2022). C\u2010peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.&nbsp;<em>Diabetes, Obesity and Metabolism<\/em>,&nbsp;<em>24<\/em>(10), 1912-1926.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">41. Lue, L. F., Guerra, A., &amp; Walker, D. G. (2017). Amyloid beta and tau as Alzheimer\u2019s disease blood biomarkers: promise from new technologies.&nbsp;<em>Neurology and therapy<\/em>,&nbsp;<em>6<\/em>(Suppl 1), 25-36.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">42. Mollenhauer, B., Dakna, M., Kruse, N., <em>et al<\/em>. (2020). Validation of serum neurofilament light chain as a biomarker of Parkinson&#8217;s disease progression.&nbsp;<em>Movement Disorders<\/em>,&nbsp;<em>35<\/em>(11), 1999-2008.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">43. Ning, L., &amp; Wang, B. (2022). Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.&nbsp;<em>PLoS One<\/em>,&nbsp;<em>17<\/em>(9), e0274565.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">44. Pasternak, A. O., Lukashov, V. V., &amp; Berkhout, B. (2013). Cell-associated HIV RNA: a dynamic biomarker of viral persistence.&nbsp;<em>Retrovirology<\/em>,&nbsp;<em>10<\/em>(1), 41.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">45. Kaur, M., Tiwari, S., &amp; Jain, R. (2020). Protein based biomarkers for non-invasive Covid-19 detection.&nbsp;<em>Sensing and Bio-Sensing Research<\/em>,&nbsp;<em>29<\/em>, 100362.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">46. Monroy-Iglesias, M. J., Crescioli, S., Beckmann, K., <em>et al<\/em>. (2022). Antibodies as biomarkers for cancer risk: a systematic review.&nbsp;<em>Clinical and Experimental Immunology<\/em>,&nbsp;<em>209<\/em>(1), 46.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">47. Vacante, M., Borz\u00ec, A. M., Basile, F., <em>et al<\/em>. (2018). Biomarkers in colorectal cancer: Current clinical utility and future perspectives.&nbsp;<em>World journal of clinical cases<\/em>,&nbsp;<em>6<\/em>(15), 869.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">48. Buyse, M., Michiels, S., Sargent, D. J., <em>et al<\/em>. (2011). Integrating biomarkers in clinical trials.&nbsp;<em>Expert review of molecular diagnostics<\/em>,&nbsp;<em>11<\/em>(2), 171-182.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">49. Sanders, T., Liu, Y., Buchner, V., <em>et al<\/em>. (2009). Neurotoxic effects and biomarkers of lead exposure: a review.&nbsp;<em>Reviews on environmental health<\/em>,&nbsp;<em>24<\/em>(1), 15.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">50. Sugeeta, S. S., Sharma, A., Ng, K., <em>et al<\/em>. (2021). Biomarkers in bladder cancer surveillance.&nbsp;<em>Frontiers in Surgery<\/em>,&nbsp;<em>8<\/em>, 735868.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">51. Guarna, M. M., Hoover, S. E., Huxter, E., <em>et al<\/em>. (2017). Peptide biomarkers used for the selective breeding of a complex polygenic trait in honey bees.&nbsp;<em>Scientific reports<\/em>,&nbsp;<em>7<\/em>(1), 8381.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">52. Sim, D., Brothers, M. C., Slocik, J. M., <em>et al<\/em>. (2022). Biomarkers and detection platforms for human health and performance monitoring: a review.&nbsp;<em>Advanced Science<\/em>,&nbsp;<em>9<\/em>(7), 2104426.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">53. Enroth, S., Johansson, \u00c5., Enroth, S. B., <em>et al<\/em>. (2014). Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs.&nbsp;<em>Nature communications<\/em>,&nbsp;<em>5<\/em>(1), 4684.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">54. McDermott, J. E., Wang, J., Mitchell, H., <em>et al<\/em>. (2013). Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data.&nbsp;<em>Expert opinion on medical diagnostics<\/em>,&nbsp;<em>7<\/em>(1), 37-51.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">55. Andreoletti, M., Haller, L., Vayena, E., <em>et al<\/em>. (2024). Mapping the ethical landscape of digital biomarkers: A scoping review.&nbsp;<em>PLOS Digital Health<\/em>,&nbsp;<em>3<\/em>(5), e0000519.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">56. Xiao, Y., Bi, M., Guo, H., <em>et al<\/em>. (2022). Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis.&nbsp;<em>EBioMedicine<\/em>,&nbsp;<em>79<\/em>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">57. Kilgour, E., Rothwell, D. G., Brady, G., <em>et al<\/em>. (2020). Liquid biopsy-based biomarkers of treatment response and resistance.&nbsp;<em>Cancer cell<\/em>,&nbsp;<em>37<\/em>(4), 485-495.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">58. Mann, M., Kumar, C., Zeng, W. F., <em>et al<\/em>. (2021). Artificial intelligence for proteomics and biomarker discovery.&nbsp;<em>Cell systems<\/em>,&nbsp;<em>12<\/em>(8), 759-770.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">59. Sempionatto, J. R., Lasalde-Ram\u00edrez, J. A., Mahato, K., <em>et al<\/em>. (2022). Wearable chemical sensors for biomarker discovery in the omics era.&nbsp;<em>Nature Reviews Chemistry<\/em>,&nbsp;<em>6<\/em>(12), 899-915.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">60. Hori, S. S., &amp; Gambhir, S. S. (2011). Mathematical model identifies blood biomarker\u2013based early cancer detection strategies and limitations.&nbsp;<em>Science translational medicine<\/em>,&nbsp;<em>3<\/em>(109), 109ra116-109ra116.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">61. Schmidt, K. T., Chau, C. H., Price, D. K., <em>et al<\/em>. (2016). Precision oncology medicine: the clinical relevance of patient\u2010specific biomarkers used to optimize cancer treatment.&nbsp;<em>The Journal of Clinical Pharmacology<\/em>,&nbsp;<em>56<\/em>(12), 1484-1499.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biomarkers, as measurable indicators of biological states, are revolutionizing medicine, enabling earlier diagnosis, personalized therapies, and efficient drug development. Their future is driven by multi-omics, liquid biopsies, and artificial intelligence, but realizing full potential requires rigorous validation and addressing ethical governance.<\/p>\n","protected":false},"author":2,"featured_media":470,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,8,5,18],"tags":[],"coauthors":[9,10],"class_list":["post-469","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biochemistry","category-healthcare","category-microbiology","category-molecular-biology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomarkers are Transforming Medicine and Research<\/title>\n<meta name=\"description\" content=\"Biomarkers are measurable indicators of biological states, and this way health, disease progression, and treatment outcomes are determined.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.najao.com\/learn\/biomarkers\/\" \/>\n<link rel=\"next\" href=\"https:\/\/www.najao.com\/learn\/biomarkers\/2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomarkers are Transforming Medicine and Research\" \/>\n<meta property=\"og:description\" content=\"Biomarkers are measurable indicators of biological states, and this way health, disease progression, and treatment outcomes are determined.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.najao.com\/learn\/biomarkers\/\" \/>\n<meta property=\"og:site_name\" content=\"Najao Inovix\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/najaoinovix\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-23T11:28:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-06T11:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Biomarkers.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anwesha Acharyya, Sujay Ghosh\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@najaoinovix\" \/>\n<meta name=\"twitter:site\" content=\"@najaoinovix\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anwesha Acharyya, Sujay Ghosh\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/\"},\"author\":{\"name\":\"Anwesha Acharyya\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/person\\\/212be9d306102c49ff1ea14a09c562cc\"},\"headline\":\"Biomarkers: Vital Tools Transforming Medicine and Research\",\"datePublished\":\"2025-08-23T11:28:02+00:00\",\"dateModified\":\"2026-04-06T11:50:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/\"},\"wordCount\":3148,\"publisher\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Biomarkers.jpg\",\"articleSection\":[\"Biochemistry\",\"Healthcare\",\"Microbiology\",\"Molecular Biology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/\",\"name\":\"Biomarkers are Transforming Medicine and Research\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Biomarkers.jpg\",\"datePublished\":\"2025-08-23T11:28:02+00:00\",\"dateModified\":\"2026-04-06T11:50:00+00:00\",\"description\":\"Biomarkers are measurable indicators of biological states, and this way health, disease progression, and treatment outcomes are determined.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/biomarkers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Biomarkers.jpg\",\"contentUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Biomarkers.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Biomarkers\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#website\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/\",\"name\":\"Najao Inovix\",\"description\":\"Cooperation for Success\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#organization\",\"name\":\"Najao Inovix\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Najao-Favicon.png\",\"contentUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Najao-Favicon.png\",\"width\":2490,\"height\":2490,\"caption\":\"Najao Inovix\"},\"image\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/najaoinovix\\\/\",\"https:\\\/\\\/x.com\\\/najaoinovix\",\"https:\\\/\\\/www.instagram.com\\\/najaoinovix\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/najao\\\/\",\"https:\\\/\\\/www.threads.com\\\/@najaoinovix\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/person\\\/212be9d306102c49ff1ea14a09c562cc\",\"name\":\"Anwesha Acharyya\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/882127305fec3ba4deef3a7ac6b42bc431d309955b0f957171786328513420d6?s=96&d=mm&r=g05ae44e0cbcb45a2803c74414050a73f\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/882127305fec3ba4deef3a7ac6b42bc431d309955b0f957171786328513420d6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/882127305fec3ba4deef3a7ac6b42bc431d309955b0f957171786328513420d6?s=96&d=mm&r=g\",\"caption\":\"Anwesha Acharyya\"},\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/author\\\/anwesha\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomarkers are Transforming Medicine and Research","description":"Biomarkers are measurable indicators of biological states, and this way health, disease progression, and treatment outcomes are determined.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.najao.com\/learn\/biomarkers\/","next":"https:\/\/www.najao.com\/learn\/biomarkers\/2\/","og_locale":"en_US","og_type":"article","og_title":"Biomarkers are Transforming Medicine and Research","og_description":"Biomarkers are measurable indicators of biological states, and this way health, disease progression, and treatment outcomes are determined.","og_url":"https:\/\/www.najao.com\/learn\/biomarkers\/","og_site_name":"Najao Inovix","article_publisher":"https:\/\/www.facebook.com\/najaoinovix\/","article_published_time":"2025-08-23T11:28:02+00:00","article_modified_time":"2026-04-06T11:50:00+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Biomarkers.jpg","type":"image\/jpeg"}],"author":"Anwesha Acharyya, Sujay Ghosh","twitter_card":"summary_large_image","twitter_creator":"@najaoinovix","twitter_site":"@najaoinovix","twitter_misc":{"Written by":"Anwesha Acharyya, Sujay Ghosh","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.najao.com\/learn\/biomarkers\/#article","isPartOf":{"@id":"https:\/\/www.najao.com\/learn\/biomarkers\/"},"author":{"name":"Anwesha Acharyya","@id":"https:\/\/www.najao.com\/learn\/#\/schema\/person\/212be9d306102c49ff1ea14a09c562cc"},"headline":"Biomarkers: Vital Tools Transforming Medicine and Research","datePublished":"2025-08-23T11:28:02+00:00","dateModified":"2026-04-06T11:50:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.najao.com\/learn\/biomarkers\/"},"wordCount":3148,"publisher":{"@id":"https:\/\/www.najao.com\/learn\/#organization"},"image":{"@id":"https:\/\/www.najao.com\/learn\/biomarkers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Biomarkers.jpg","articleSection":["Biochemistry","Healthcare","Microbiology","Molecular Biology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.najao.com\/learn\/biomarkers\/","url":"https:\/\/www.najao.com\/learn\/biomarkers\/","name":"Biomarkers are Transforming Medicine and Research","isPartOf":{"@id":"https:\/\/www.najao.com\/learn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.najao.com\/learn\/biomarkers\/#primaryimage"},"image":{"@id":"https:\/\/www.najao.com\/learn\/biomarkers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Biomarkers.jpg","datePublished":"2025-08-23T11:28:02+00:00","dateModified":"2026-04-06T11:50:00+00:00","description":"Biomarkers are measurable indicators of biological states, and this way health, disease progression, and treatment outcomes are determined.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.najao.com\/learn\/biomarkers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.najao.com\/learn\/biomarkers\/#primaryimage","url":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Biomarkers.jpg","contentUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Biomarkers.jpg","width":1280,"height":853,"caption":"Biomarkers"},{"@type":"WebSite","@id":"https:\/\/www.najao.com\/learn\/#website","url":"https:\/\/www.najao.com\/learn\/","name":"Najao Inovix","description":"Cooperation for Success","publisher":{"@id":"https:\/\/www.najao.com\/learn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.najao.com\/learn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.najao.com\/learn\/#organization","name":"Najao Inovix","url":"https:\/\/www.najao.com\/learn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.najao.com\/learn\/#\/schema\/logo\/image\/","url":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2025\/05\/Najao-Favicon.png","contentUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2025\/05\/Najao-Favicon.png","width":2490,"height":2490,"caption":"Najao Inovix"},"image":{"@id":"https:\/\/www.najao.com\/learn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/najaoinovix\/","https:\/\/x.com\/najaoinovix","https:\/\/www.instagram.com\/najaoinovix\/","https:\/\/www.linkedin.com\/company\/najao\/","https:\/\/www.threads.com\/@najaoinovix"]},{"@type":"Person","@id":"https:\/\/www.najao.com\/learn\/#\/schema\/person\/212be9d306102c49ff1ea14a09c562cc","name":"Anwesha Acharyya","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/882127305fec3ba4deef3a7ac6b42bc431d309955b0f957171786328513420d6?s=96&d=mm&r=g05ae44e0cbcb45a2803c74414050a73f","url":"https:\/\/secure.gravatar.com\/avatar\/882127305fec3ba4deef3a7ac6b42bc431d309955b0f957171786328513420d6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/882127305fec3ba4deef3a7ac6b42bc431d309955b0f957171786328513420d6?s=96&d=mm&r=g","caption":"Anwesha Acharyya"},"url":"https:\/\/www.najao.com\/learn\/author\/anwesha\/"}]}},"_links":{"self":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts\/469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/comments?post=469"}],"version-history":[{"count":2,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts\/469\/revisions"}],"predecessor-version":[{"id":513,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts\/469\/revisions\/513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/media\/470"}],"wp:attachment":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/media?parent=469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/categories?post=469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/tags?post=469"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/coauthors?post=469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}